But at least three of the research sites being shut down stand out: those that were originally part of Organon, the pharmaceutical-making arm of the Dutch chemicals giant Akzo Nobel.
Schering-Plough continues to execute on our Action Agenda and is now building the base and diversifying and strengthening the company, particularly through the recent acquisition of Organon BioSciences.